• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hormone replacement and cancer.

作者信息

Barrett-Connor E

机构信息

Department of Community and Family Medicine, University of California San Diego, La Jolla.

出版信息

Br Med Bull. 1992 Apr;48(2):345-55. doi: 10.1093/oxfordjournals.bmb.a072550.

DOI:10.1093/oxfordjournals.bmb.a072550
PMID:1450874
Abstract

The increasing extended use of noncontraceptive oestrogen by postmenopausal women, intended to prevent other conditions, may at the same time increase their risk of reproductive cancer. The risk of endometrial cancer triples after only a few years of unopposed oestrogen, persists for many years after oestrogen has been discontinued, and appears to be preventable by the addition of a progestin. The effect of replacement hormones on the risk of breast or ovarian cancer is unknown. Most studies suggest a small but significant increased risk of breast cancer after long-term use. Awareness of the known and uncertain cancer risks should be included in decisions to use replacement hormones.

摘要

相似文献

1
Hormone replacement and cancer.
Br Med Bull. 1992 Apr;48(2):345-55. doi: 10.1093/oxfordjournals.bmb.a072550.
2
Hormone replacement therapy and cancer.激素替代疗法与癌症。
Gynecol Endocrinol. 2001 Dec;15(6):453-65.
3
Hormone replacement therapy and endometrial, ovarian and colorectal cancer.激素替代疗法与子宫内膜癌、卵巢癌和结直肠癌
Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):139-47. doi: 10.1016/s1521-690x(02)00086-6.
4
Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.更年期医学中的争议问题II. 激素替代疗法与癌症。国际绝经学会专家研讨会。2001年6月9日至12日,意大利比萨大教堂歌剧院
Climacteric. 2001 Sep;4(3):181-93.
5
Menopausal hormone therapy and cancer risk: An overestimated risk?更年期激素疗法与癌症风险:风险被高估了吗?
Eur J Cancer. 2017 Oct;84:60-68. doi: 10.1016/j.ejca.2017.07.012. Epub 2017 Aug 4.
6
Risk of endometrial cancer following estrogen replacement with and without progestins.雌激素补充治疗联合或不联合孕激素时子宫内膜癌的风险。
J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7. doi: 10.1093/jnci/91.13.1131.
7
Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer.绝经后雌激素和孕激素与妇科癌症的发病率
Maturitas. 1996 Mar;23(2):235-9. doi: 10.1016/0378-5122(95)00976-0.
8
[Hormone replacement therapy and cancer].[激素替代疗法与癌症]
Tidsskr Nor Laegeforen. 1997 Jun 10;117(15):2201-7.
9
Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.绝经后女性队列中,绝经后使用雌激素加孕激素和单纯使用雌激素者的子宫内膜癌风险。
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31. doi: 10.1158/1055-9965.EPI-05-0111.
10
Cancer risk in women receiving estrogen-progestin replacement therapy.接受雌激素 - 孕激素替代疗法的女性的癌症风险。
Maturitas. 1996 May;23 Suppl:S37-45. doi: 10.1016/0378-5122(96)01010-9.

引用本文的文献

1
Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone replacement therapy in rabbit model of menopause.雷洛昔芬、阿司匹林和雌激素联合应用于绝经后兔模型的激素替代治疗的新方案。
Acta Pharmacol Sin. 2011 Aug;32(8):1031-7. doi: 10.1038/aps.2011.87. Epub 2011 Jul 18.
2
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis.双膦酸盐、选择性雌激素受体调节剂(SERMs)和甲状旁腺激素对骨质疏松症骨重塑的不同作用。
Clin Interv Aging. 2007;2(1):55-64. doi: 10.2147/ciia.2007.2.1.55.
3
Hormone replacement therapy: knowledge, attitudes, and well-being among middle-aged Australian women.
激素替代疗法:澳大利亚中年女性的知识、态度与幸福感
Int J Behav Med. 1996;3(3):202-20. doi: 10.1207/s15327558ijbm0303_2.
4
Selective estrogen receptor modulators.选择性雌激素受体调节剂
Rev Endocr Metab Disord. 2002 Sep;3(3):231-41. doi: 10.1023/a:1020076426727.
5
Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.雷洛昔芬的作用机制及临床前概况:一种选择性雌激素受体调节剂
Rev Endocr Metab Disord. 2001 Jan;2(1):129-38. doi: 10.1023/a:1010019410881.
6
Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.糖尿病绝经后女性的激素替代疗法:风险效益评估
Drugs Aging. 2000 Nov;17(5):399-410. doi: 10.2165/00002512-200017050-00006.
7
Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals.又是激素替代疗法。不同人群和个体之间的风险效益关系有所不同。
BMJ. 1998 Jun 20;316(7148):1842-4. doi: 10.1136/bmj.316.7148.1842.
8
Sex steroid hormones, bone mineral density, and risk of breast cancer.性类固醇激素、骨密度与乳腺癌风险
Environ Health Perspect. 1997 Apr;105 Suppl 3(Suppl 3):593-9. doi: 10.1289/ehp.97105s3593.
9
Hormone replacement therapy. Cardioprotective effect is genuine.激素替代疗法。心脏保护作用是真实存在的。
BMJ. 1994 Jul 16;309(6948):191-2.
10
The menopause and hormone replacement therapy.更年期与激素替代疗法。
Postgrad Med J. 1992 Aug;68(802):615-23. doi: 10.1136/pgmj.68.802.615.